{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T12:39:45Z","timestamp":1790167185454,"version":"4.1.0"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T00:00:00Z","timestamp":1444262400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2016,2]]},"DOI":"10.1007\/s40262-015-0315-x","type":"journal-article","created":{"date-parts":[[2015,10,8]],"date-time":"2015-10-08T02:41:09Z","timestamp":1444272069000},"page":"249-255","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":24,"title":["Augmentation of Endoxifen Exposure in Tamoxifen-Treated Women Following SSRI Switch"],"prefix":"10.1007","volume":"55","author":[{"given":"Lisette","family":"Binkhorst","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolein","family":"Bannink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"de Bruijn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Ruit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helga","family":"Droogendijk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robbert J.","family":"van Alphen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilly D.","family":"den Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei Ho","family":"Lam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Agnes","family":"Jager","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Teun","family":"van Gelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron H. J.","family":"Mathijssen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2015,10,8]]},"reference":[{"key":"315_CR1","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1200\/JOP.000082","volume":"6","author":"HJ Burstein","year":"2010","unstructured":"Burstein HJ, Griggs JJ, Prestrud AA, Temin S. American Society of Clinical Oncology clinical practice guideline update on adjuvant endocrine therapy for women with hormone receptor-positive breast cancer. J Oncol Pract. 2010;6:243\u20136.","journal-title":"J Oncol Pract."},{"key":"315_CR2","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group, Davies C, Godwin J, Gray R, Clarke M, Cutter D, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet. 2011;378:771\u201384.","journal-title":"Lancet"},{"key":"315_CR3","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/nrc2683","volume":"9","author":"JM Hoskins","year":"2009","unstructured":"Hoskins JM, Carey LA, McLeod HL. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat Rev Cancer. 2009;9:576\u201386.","journal-title":"Nat Rev Cancer"},{"key":"315_CR4","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1124\/jpet.104.065607","volume":"310","author":"Z Desta","year":"2004","unstructured":"Desta Z, Ward BA, Soukhova NV, Flockhart DA. Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004;310:1062\u201375.","journal-title":"J Pharmacol Exp Ther"},{"key":"315_CR5","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/clpt.2011.27","volume":"89","author":"TE Murdter","year":"2011","unstructured":"Murdter TE, Schroth W, Bacchus-Gerybadze L, Winter S, Heinkele G, Simon W, et al. Activity levels of tamoxifen metabolites at the estrogen receptor and the impact of genetic polymorphisms of phase I and II enzymes on their concentration levels in plasma. Clin Pharmacol Ther. 2011;89:708\u201317.","journal-title":"Clin Pharmacol Ther"},{"key":"315_CR6","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00280-004-0926-7","volume":"55","author":"YC Lim","year":"2005","unstructured":"Lim YC, Desta Z, Flockhart DA, Skaar TC. Endoxifen (4-hydroxy-N-desmethyl-tamoxifen) has anti-estrogenic effects in breast cancer cells with potency similar to 4-hydroxy-tamoxifen. Cancer Chemother Pharmacol. 2005;55:471\u20138.","journal-title":"Cancer Chemother Pharmacol"},{"key":"315_CR7","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1093\/jnci\/djg108","volume":"95","author":"V Stearns","year":"2003","unstructured":"Stearns V, Johnson MD, Rae JM, Morocho A, Novielli A, Bhargava P, et al. Active tamoxifen metabolite plasma concentrations after coadministration of tamoxifen and the selective serotonin reuptake inhibitor paroxetine. J Natl Cancer Inst. 2003;95:1758\u201364.","journal-title":"J Natl Cancer Inst"},{"issue":"5","key":"315_CR8","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1038\/clpt.2011.32","volume":"89","author":"L Madlensky","year":"2011","unstructured":"Madlensky L, Natarajan L, Tchu S, Pu M, Mortimer J, Flatt SW, et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther. 2011;89(5):718\u201325.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"315_CR9","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.clpt.2006.03.013","volume":"80","author":"S Borges","year":"2006","unstructured":"Borges S, Desta Z, Li L, Skaar TC, Ward BA, Nguyen A, et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther. 2006;80(1):61\u201374.","journal-title":"Clin Pharmacol Ther"},{"issue":"1","key":"315_CR10","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10549-006-9428-0","volume":"101","author":"MP Goetz","year":"2007","unstructured":"Goetz MP, Knox SK, Suman VJ, Rae JM, Safgren SL, Ames MM, et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat. 2007;101(1):113\u201321. doi: 10.1007\/s10549-006-9428-0 .","journal-title":"Breast Cancer Res Treat"},{"issue":"13","key":"315_CR11","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1001\/jama.2009.1420","volume":"302","author":"W Schroth","year":"2009","unstructured":"Schroth W, Goetz MP, Hamann U, Fasching PA, Schmidt M, Winter S, et al. Association between CYP2D6 polymorphisms and outcomes among women with early stage breast cancer treated with tamoxifen. JAMA. 2009;302(13):1429\u201336.","journal-title":"JAMA"},{"issue":"6","key":"315_CR12","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/jnci\/djs125","volume":"104","author":"MM Regan","year":"2012","unstructured":"Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, et al. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the Breast International Group 1\u201398 Trial. J Natl Cancer Inst. 2012;104(6):441\u201351.","journal-title":"J Natl Cancer Inst"},{"issue":"6","key":"315_CR13","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1093\/jnci\/djs126","volume":"104","author":"JM Rae","year":"2012","unstructured":"Rae JM, Drury S, Hayes DF, Stearns V, Thibert JN, Haynes BP, et al. CYP2D6 and UGT2B7 genotype and risk of recurrence in tamoxifen-treated breast cancer patients. J Natl Cancer Inst. 2012;104(6):452\u201360.","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"315_CR14","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1586\/era.10.228","volume":"11","author":"H Zembutsu","year":"2011","unstructured":"Zembutsu H, Sasa M, Kiyotani K, Mushiroda T, Nakamura Y. Should CYP2D6 inhibitors be administered in conjunction with tamoxifen? Expert Rev Anticancer Ther. 2011;11(2):185\u201393.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"3","key":"315_CR15","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1007\/s10549-013-2585-z","volume":"139","author":"L Binkhorst","year":"2013","unstructured":"Binkhorst L, Mathijssen RH, van Herk-Sukel MP, Bannink M, Jager A, Wiemer EA, et al. Unjustified prescribing of CYP2D6 inhibiting SSRIs in women treated with tamoxifen. Breast Cancer Res Treat. 2013;139(3):923\u20139.","journal-title":"Breast Cancer Res Treat"},{"key":"315_CR16","doi-asserted-by":"crossref","first-page":"c693","DOI":"10.1136\/bmj.c693","volume":"340","author":"CM Kelly","year":"2010","unstructured":"Kelly CM, Juurlink DN, Gomes T, Duong-Hua M, Pritchard KI, Austin PC, et al. Selective serotonin reuptake inhibitors and breast cancer mortality in women receiving tamoxifen: a population based cohort study. BMJ. 2010;340:c693.","journal-title":"BMJ"},{"key":"315_CR17","doi-asserted-by":"crossref","unstructured":"Aubert RE, Stanek E, Yao J, Teagarden JR, Subar M, Epstein RS, Skaar TC, Desta Z, Flockhart DA. Risk of breast cancer recurrence in women initiating tamoxifen with CYP2D6 inhibitors. J Clin Oncol 2009;27(18s):(Suppl; abstract no. CRA508).","DOI":"10.1200\/jco.2009.27.18s.cra508"},{"issue":"5","key":"315_CR18","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1016\/j.jpba.2011.08.002","volume":"56","author":"L Binkhorst","year":"2011","unstructured":"Binkhorst L, Mathijssen RH, Ghobadi Moghaddam-Helmantel IM, de Bruijn P, van Gelder T, Wiemer EA, et al. Quantification of tamoxifen and three of its phase-I metabolites in human plasma by liquid chromatography\/triple-quadrupole mass spectrometry. J Pharm Biomed Anal. 2011;56(5):1016\u201323.","journal-title":"J Pharm Biomed Anal"},{"issue":"3","key":"315_CR19","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/j.1365-2125.1992.tb04134.x","volume":"34","author":"HK Crewe","year":"1992","unstructured":"Crewe HK, Lennard MS, Tucker GT, Woods FR, Haddock RE. The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes. Br J Clin Pharmacol. 1992;34(3):262\u20135.","journal-title":"Br J Clin Pharmacol"},{"issue":"8","key":"315_CR20","first-page":"1102","volume":"29","author":"LL Moltke von","year":"2001","unstructured":"von Moltke LL, Greenblatt DJ, Giancarlo GM, Granda BW, Harmatz JS, Shader RI. Escitalopram (S-citalopram) and its metabolites in vitro: cytochromes mediating biotransformation, inhibitory effects, and comparison to R-citalopram. Drug Metab Dispos. 2001;29(8):1102\u20139.","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"315_CR21","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1007\/s002280050163","volume":"51","author":"U Jeppesen","year":"1996","unstructured":"Jeppesen U, Gram LF, Vistisen K, Loft S, Poulsen HE, Brosen K. Dose-dependent inhibition of CYP1A2, CYP2C19 and CYP2D6 by citalopram, fluoxetine, fluvoxamine and paroxetine. Eur J Clin Pharmacol. 1996;51(1):73\u20138.","journal-title":"Eur J Clin Pharmacol"},{"issue":"2","key":"315_CR22","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1007\/s10549-006-9193-0","volume":"99","author":"TL Lash","year":"2006","unstructured":"Lash TL, Fox MP, Westrup JL, Fink AK, Silliman RA. Adherence to tamoxifen over the five-year course. Breast Cancer Res Treat. 2006;99(2):215\u201320.","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"315_CR23","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/clpt.2011.372","volume":"92","author":"L Binkhorst","year":"2012","unstructured":"Binkhorst L, van Gelder T, Loos WJ, de Jongh FE, Hamberg P, Moghaddam-Helmantel IM, et al. Effects of CYP induction by rifampicin on tamoxifen exposure. Clin Pharmacol Ther. 2012;92(1):62\u20137.","journal-title":"Clin Pharmacol Ther"},{"issue":"24","key":"315_CR24","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1200\/JCO.2010.32.9839","volume":"29","author":"AJ Graan de","year":"2011","unstructured":"de Graan AJ, Teunissen SF, de Vos FY, Loos WJ, van Schaik RH, de Jongh FE, et al. Dextromethorphan as a phenotyping test to predict endoxifen exposure in patients on tamoxifen treatment. J Clin Oncol. 2011;29(24):3240\u20136.","journal-title":"J Clin Oncol"},{"issue":"3","key":"315_CR25","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","volume":"132","author":"W Lorizio","year":"2012","unstructured":"Lorizio W, Wu AH, Beattie MS, Rugo H, Tchu S, Kerlikowske K, et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res Treat. 2012;132(3):1107\u201318.","journal-title":"Breast Cancer Res Treat"},{"key":"315_CR26","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1186\/1471-2407-13-612","volume":"13","author":"NG Jager","year":"2013","unstructured":"Jager NG, Koornstra RH, Vincent AD, et al. Hot flashes are not predictive for serum concentrations of tamoxifen and its metabolites. BMC Cancer. 2013;13:612.","journal-title":"BMC Cancer"},{"key":"315_CR27","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1093\/jnci\/dji005","volume":"97","author":"Y Jin","year":"2005","unstructured":"Jin Y, Desta Z, Stearns V, et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst. 2005;97:30\u20139.","journal-title":"J Natl Cancer Inst"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0315-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40262-015-0315-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-015-0315-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,31]],"date-time":"2019-08-31T09:19:49Z","timestamp":1567243189000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40262-015-0315-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["315"],"URL":"https:\/\/doi.org\/10.1007\/s40262-015-0315-x","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,10,8]]}}}